Open Access

GNAS1 T393C polymorphism and disease progression in patients with malignant melanoma

  • UH Frey1, 2,
  • A Fritz3,
  • S Rotterdam3,
  • KW Schmid4,
  • A Potthoff3,
  • P Altmeyer3,
  • W Siffert1 and
  • NH Brockmeyer3Email author
Contributed equally
European Journal of Medical Research201015:422

https://doi.org/10.1186/2047-783X-15-10-422

Received: 9 April 2010

Accepted: 3 May 2010

Published: 25 October 2010

Abstract

Background

Once metastasized, despite a variety of therapeutic options, the prognosis of patients with malignant melanoma (MM) is still poor. Therefore, the search for reliable markers to identify patients with high risk of disease progression is of high clinical importance. We have recently shown that TT genotypes of the single-nucleotide polymorphism (SNP) T393C in the gene GNAS1 are significantly associated with better outcome in a variety of carcinomas.

Patients

In the present study we assessed whether the T393C SNP is also related to the clinical course in MM. 328 patients with MM were retrospectively genotyped and genotypes were correlated with clinical outcome.

Results

While the allele frequency in the MM group (fC 0.52) did not significantly differ from that of healthy blood donors, the T393C SNP was associated with tumor progression of MM. Carriers of the C-allele showed a significantly more severe tumor progression as estimated from the time period to develop metastasis (HR 2.2, 95% CI 1.1-3.2, p = 0.017). Proportions of 5-year metastasis-free intervals were 87.1% for TT genotypes and 66.0% for C-allele carriers. Moreover, multivariable Cox regression analysis including tumor stage and melanoma subtype proved the T393C polymorphism to be an independent factor for metastasis (p = 0.012).

Conclusions

In summary, the GNAS1 T393C SNP represents a genetic host factor for predicting tumor progression also in patients with MM; genotyping of this SNP may contribute to better define patients who could benefit from an early individualized therapy.

Keywords

polymorphismG Proteinmelanomapro gnostic factor

Introduction

Early detection of metastasis is one of the aims of follow-up examination in patients with malignant melanoma since once metastasized, despite a variety of therapeutic options e. g. chemo- and/or immunotherapy, patients suffering from malignant melanoma show an unfavorable prognosis. Therefore, it would be most desirable to identify patients with high risk of disease progression as early as possible [1]. Since laboratory tests are easy to handle and modestly expensive, a variety of different serum factors has been investigated for their potential relevance as prognostic markers in malignant melanoma [24]. To date, none of these markers is routinely used in the clinical setting. The most promising one at present, S100-protein, has been demonstrated in several studies to be a valid and reliable predictive marker for clinical progression and response to therapy in melanoma patients with advanced stages of disease [5, 6]. However, a major disadvantage of S100-protein is its poor prognostic impact in early-stage melanoma patients [68].

The identification of new prognostic markers may help to better distinguish low from high risk disease apart from the classical histopathologic and clinical criteria and may unravel new targets for therapy. The mechanism of malignant transformation of melanocytes is poorly understood, but growth factors and their receptors play an important role in the progression of melanoma [9]. Moreover, alterations in the mitogen-activated protein kinase pathway are almost uniformly present in melanoma. While RAS itself is only infrequently mutated in melanoma [10] the downstream BRAF gene of the mitogen activated protein kinase pathway is mutated in 60% to 70% of superficial spreading melanomas [11]. On the other hand, a genetic host factor may offer a better stratification of patients into more refined risk categories without the need for tumor tissue. For example, the A61G single nucleotide polymorphism (SNP) in the EGF gene which operates via RAS and BRAF in melanocytic tumors has recently been associated with risk for metastasis in melanoma patients [12].

We have recently shown that the T393C polymorphism in the gene GNAS1, which encodes the G_s subunit of heterotrimeric G protein, is significantly associated with the clinical outcome of patients suffering from bladder cancer [13], colorectal cancer [14], chronic lymphocytic leukaemia [15], and renal cell carcinoma [16]. We also demonstrated that the T allele of GNAS1 T393C polymorphism is associated with increased Gαs mRNA expression in a variety of tissues, including tumor tissue [14]. In vitro experiments suggest that an increased expression of Gαs is associated with enhanced apoptosis and that the second messenger cAMP, which functions downstream of G proteins, plays a major role in this pro-apoptotic process [1720]. Hence, an increased Gαs expression with concomitantly enhanced apoptosis may be also associated with better survival in melanoma patients with TT genotypes.

Materials and methods

Patients

This study comprises a total of 328 consecutive malignant melanoma patients (with a mean age of 54.2 ± 16.4 years) treated at the Department of Dermatology and Allergology, Ruhr-University Bochum (Bochum, Germany) between 1995 and 2000 with disease progression being continuously documented. The clinical staging was performed according to the American Joint Committee on Cancer (AJCC 1997). Briefly, stages I and II included patients with primary melanoma, stage III included patients with regional lymph node and/or in-transit metastases and stage IV included patients with distant metastases. Patients were treated according to therapy protocols of the Dermatologic Cooperative Oncology Group (DeCOG) including cytostatic drugs (dacarbacine, cis-platinum, temozolomide, vincristine) and immunomodulatory agents [interferon(IFN)] in different combinations and schedules. Follow-up was performed in at least 3-months intervals including physical examination, x-ray of the chest, ultra- sound of the abdomen and lymph nodes as well as blood chemistry. Patients in advanced disease stages additionally underwent computer tomography of the brain and szintigraphy of the skeleton. Detailed clinical characteristics of the study patients are summarized in Table 1. The retrospective analysis and genotyping of DNA from paraffin-embedded tissues in an anonymous form was approved by the ethical committee of the University Hospital Essen (Essen, Germany).

Table 1

 

All

TT

TC

CC

P

N (%)

328

69 (21.0)

149 (45.4)

110 (33.5)

 

Gender (m/f)

167/161

30/39

86/63

51/59

0.074

Mean age at diagnosis

54.2

55.0

54.4

53.4

0.517

UICC Category.

     

I

202 (61.6)

45 (22.3)

85 (42.1)

72 (35.6)

 

II

72 (22.0)

13 (18.1)

34 (47.2)

25 (34.7)

 

III

47 (14.3)

9 (19.1)

30 (63.8)

8 (17.0)

 

IV

7 (2.1)

2 (28.6)

0 (0)

5 (71.4)

0.683

Type

     

SSM

153

31

71

51

 

NM

38

8

16

14

 

LMM

34

9

14

11

 

ALM

30

7

16

7

 

UCM

73

14

32

27

 

Tumor thickness (mm)

     

<0,75

191 (58.2)

40 (20.9)

80 (41.9)

71 (37.2)

 

0,75-1,5

55 (16.8)

14 (25.5)

27 (49.1)

14 (25.5)

 

1,5- 4

58 (17.7)

8 (13.8)

31 (53.4)

19 (32.8)

 

> 4

24 (7.3)

7 (29.2)

11 (45.8)

6 (25.0)

0.385

Clark level

     

I

51 (15.5)

10 (19.6)

22 (43.1)

19 (37.3)

 

II

40 (12.2)

10 (25.0)

15 (37.5)

15 (37.5)

 

III

114 (34.8)

24 (21.1)

50 (43.9)

40 (35.1)

 

IV

92 (28.0)

20 (21.7)

45 (48.9)

27 (29.1)

 

V

10 (3.0)

2 (20.0)

6 (60.0)

2 (20.0)

0.333

Node

     

0

305 (93.0)

66 (21.6)

135 (44.3)

104 (34.1)

 

1

13 (4.0)

3 (23.1)

6 (46.2)

4 (30.8)

 

2

10 (3.0)

0 (0)

8 (80.0)

2 (20.0)

0.865

Distant metastasis

     

No

321 (97.9)

67 (20.9)

149 (46.4)

105 (32.7)

 

Yes

7 (2.1)

2 (28.6)

0 (0,0)

5 (71.4)

0.266

M; male; f, female; SSM, superficial spreading melanoma; NM, nodular melanoma; LMM, lentigo maligna melanoma; ALM, acral lentiginous melanoma; UCM, unclassified melanoma

Genotyping

DNA was extracted from paraffin-embedded tissue samples using a commercially available kit (QIAAmp, Qiagen, Hilden, Germany). Genotypes of the T393C polymorphism were determined by PCR using the following primers: forward primer 5'-CTCCTAACTGA CATGGTGCAA-3' and reverse primer 5'-TAAGGC CACACAAGTCGGGGT-3'. After denaturation at 94°C, 35 cycles of DNA amplification were performed using Taq PCR Mastermix (Eppendorf, Hamburg, Germany) at 94° for 45 sec, 58°C for 40 seconds, and 72° for 45 seconds. The 345 bp PCR products were digested using the restriction enzyme FokI and analyzed on a 2% agarose gel. The unrestricted products (345 bp) represented the TT genotype; the completely restricted products (259 and 86 bp) represented the CC genotype.

Statistical analysis

The clinical outcome analyzed in this study was survival, and metastasis dependent on UICC stages, melanoma subtypes, and T393C genotypes. Kaplan-Meier plots and the log-rank test were used to evaluate the relationship between UICC stages, melanoma subtypes or T393C genotypes, and clinical outcome from the date of the primary diagnosis to the end of follow-up. The effects of gender, age at diagnosis, UICC stages, and T393C genotypes as prognostic factors for the clinical outcome were analyzed by stepwise multivariate Cox regression analysis. Hazard ratios and 95% confidence intervals (95% CI) were calculated from the Cox regression model including all factors for multivariate analysis and for the indicated factor for univariate analysis. Contingency tables and the Pearson's chi-square test were used for categorical variables using T393C genotypes. Linear ANOVA was used for comparison of continuous variables where appropriate. Differences were regarded significant at P < 0.05. All statistical analyses were done using SPSS 13.0 (SPSS, Chicago, IL) or GraphPad Prism 4.0 (Graph-Pad Software, San Diego, CA). Continuous variables are given as means ± SD or ± SE as indicated.

Results

Genotype distribution

Demographic characteristics and tumor stage in the whole patient group and by T393C genotypes are displayed in Table 1. The frequency of the C allele in the patient group was 0.52 and genotype distribution was compatible with the Hardy-Weinberg equilibrium. Genotypes and allele frequency of patients were comparable with those of healthy white blood donors; details of this control group have been published previously [21]. This argues against an association of T393C genotypes with an increased susceptibility for malignant melanoma. We found no genotype association with age at time of first diagnosis. Moreover, genotypes were not significantly associated with tumor localization, UICC classification, or tumor thickness (Table 1).

T393C genotype and clinical follow up

During follow up, 85 patients (25.9%) experienced metastases and 88 (28.1%) died. In order to confirm that our sample was representative for patients with malignant melanoma we calculated Kaplan-Meier curves for overall survival depending on the UICC stages and tumor subtype. As shown in Figure 1A-B, overall survival was significantly dependent upon AJCC stage and tumor type. Five-year survival rates were 90.4% for UICC I, 77.1% for UICC II, 52.4% for UICC III, and 28.6% for UICC IV. Regarding tumor types, 5-year survival rates were 83.4% for SSM, 73.3% for NM, 87.3% for LMM, 75.0% for ALM and 79.4% for UCM. These findings are comparable with those from the literature [22].
Figure 1

Kaplan-Meier curves for overall survival in 328 patients with malignant melanoma based on the UICC stage (A) and tumor subtype (B). SSM, superficial spreading melanoma; NM, nodular melanoma; lMM, lentigo maligna melanoma; AlM, acral lentiginous melanoma; UCM, unclassified melanoma.

Concerning genotypes of the T393C polymorphism we observed no association with overall survival. However, we detected a significant allele-dependent influence upon tumor progression. GNAS1 393C allele carriers displayed a higher risk for metastasis (C versus TT: 2.2, 95% CI 1.1-3.2, p = 0.017) compared to T393 homozygous patients. Proportions of 5-year metastasis free intervals were 87.1% for TT genotypes and 66.0% for C-allele carriers, respectively (Figure 2).
Figure 2

Kaplan-Meier curves for metastasis-free survival in 328 patients with malignant melanoma based on T393C alleles.

In the multivariable analysis with gender, age at diagnosis, tumor stage, and melanoma subtype, the T393C polymorphism was an independent marker for tumor progression. The hazard ratio for patients with C-alleles was 2.55 for metastasis compared to homozygous 393T allele carriers (Table 2).
Table 2

Multivariable Cox proportional hazard model for metastasis in 328 patients with malignant melanoma

  

Metastasis

 
 

Hazard ratio

95% CI

P

Age at diagnosis

1.0

0.98-1.02

0.802

Gender

   

   Male

1*

  

   Female

0.96

0.61 - 1.53

0.866

UICC Stage

   

   I

1*

  

   II

1.91

0.96 - 3.81

0.067

   III

12.19

6.30 - 23.56

<0.001

   IV

21.47

6.03 - 76.49

<0.001

MM Type

   

   SSM

1*

  

   NM

1.89

0.92 - 3.88

0.081

   lMM

2.75

1.14 - 6.2

0.024

   AlM

1.56

0.74 - 3.33

0.239

   UCM

2.38

1.23 - 4.58

0.010

T393C

   

   TT

1*

  

   C

2.55

1.22 - 5.32

0.012

*reference group. CI, confidence interval. SSM were chosen as reference because they represent the largest subgroup of melanomas. SSM, superficial spreading melanoma; NM, nodular melanoma; LMM, lentigo maligna melanoma; ALM, acral lentiginous melanoma; UCM, unclassified melanoma

Discussion

Although UICC stages generally correlate with outcome in a large percentage of cancer patients, refined prediction of the individual disease course would facilitate clinical decision making, e.g. early requirement of adjuvant therapy. The familial melanoma syndromes are associated with germ line mutations in three highly penetrant gene products: p16, alternate reading frame, and cyclin-dependent kinase 4. Certain variants in a low-penetrance gene, MC1R, the melanocortin 1 receptor gene, increase melanoma risk to a lesser extent and act as genetic modifiers when cosegregating with a deleterious p16 gene [23]. Since the immune response against malignant melanoma cells can be influenced by cytokines with potentially inhibitory effects on tumor cell growth, SNPs in cytokine genes associated with reduced cytokine production are expected to influence susceptibility to cancer, including malignant melanoma. Genotypes associated with reduced production of pro-inflammatory and immunomodulatory TNF-alpha, IFN-gamma, and IL-6, and anti-inflammatory IL-10 and TGF-beta1 could be involved in mechanisms of cancer progression and escape from immunosurveillance [24]. Genotypic variations in the IL10 promotor are significantly associated with an increased risk for malignant melanoma and may be associated with a poor outcome [25]. One of the aims of the present study was, therefore, to investigate whether the common T393C SNP in the gene GNAS1, may be predictive for survival or disease-free survival in patients with malignant melanoma.

The mean age of the patients of the present malignant melanoma series was 54.2 years and the median follow-up time was 80 months. Distribution of tumor stage and subtype of the whole series were compatible with data reported in the literature. Results of the German Central Register of Malignant Melanoma showed a mean age of 58.1 year and a similar distribution of subtypes as reported here [26]. Beside the role of tumor stage and tumor thickness as the most important prognostic factor in patients with malignant melanoma, our data suggest a potential predictive use of the GNAS1 T393C SNP as an independent prognostic factor in malignant melanoma. C-allele carriers have an increased risk for tumor progression when compared to patients with the homozygous 393TT genotype, the latter group showing both a longer relapse-free survival and a later requirement for secondary therapy. Together with our previous observations showing that the T393C SNP is a predictive marker for outcome in bladder cancer [13], renal cell carcinoma [16] and colorectal cancer [14], the present results confirm the potential role of this SNP as a universal genetic marker for predicting tumor progression. The GNAS1 TT genotype is associated with increased Gαs mRNA expression in different tissues14 which led us to hypothesize that the T393C exchange itself could have an effect upon mRNA stability. Interestingly, determinants of mRNA stability have been described in the coding region of some other genes [2729]. Different in vitro experiments suggest that increased expression of Gαs is associated with enhanced apoptosis [1719]. The second messenger cyclic AMP, which is generated subsequently to activation of Gαs, seems to play a major role in this proapoptotic process. Cyclic AMP can augment or suppress ERK activity, depending on the cell type. As an example, CRAF is inhibited by protein kinase A, which is one of the downstream effectors of cAMP [30]. Cyclic AMP is produced in response to melano cytic agonists such as α-melanocyte-stimulating hormone acting through the melanocortin 1 receptor [31] resulting in activation of Gαs. Although this is only able to weakly stimulate proliferation, cAMP is closely associated with melanocyte differentiation (e. g. stimulation of melanin synthesis) [32].

A recent report has shown that cAMP blocks CRAF activity in melanocytes resulting in suppression of the oncogenic activity of CRAF in these cells [33]. This process could be of particular importance in TT genotypes in which Gαs expression is increased. However, CRAF is not required for MEK/ERK signalling in melanoma cells when BRAF is mutated [34, 35]. Late mutations in the BRAF gene could, therefore, mitigate the T393C genotype effect which may explain the lack of genotype-dependent differences in overall survival. This hypothesis is supported by observations from studies in different types of cancer in which BRAF mutations are rarely events and in which then the T393C SNP affects overall survival [36]. The goal of ongoing studies is to unravel both the detailed molecular mechanisms by which the silent C393T SNP contributes to differential Gαs expression in human tissues and how this may change the phenotype of different tumor cells.

Conflict of interests

The authors declare that they have no competing interests.

Notes

Authors’ Affiliations

(1)
Institut für Pharmakogenetik, Universität Duisburg-Essen, Universitätsklinikum Essen
(2)
Institut für Anästhesiologie und Intensivmedizin, Universität Duisburg-Essen, Universitätsklinikum Essen
(3)
Klinik für Dermatologie und Allergologie, St. Josef Hospital
(4)
Institut für Pathologie und Neuropathologie, Universität Duisburg-Essen, Universitätsklinikum Essen

References

  1. Rebmann V, Ugurel S, Tilgen W, et al.: Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients. Int J Cancer 2002, 100: 580–5. 10.1002/ijc.10524PubMedView ArticleGoogle Scholar
  2. Bosserhoff AK, Kaufmann M, Kaluza B, et al.: Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997, 57: 3149–53.PubMedGoogle Scholar
  3. Ugurel S, Rappl G, Tilgen W, et al.: Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001, 19: 577–83.PubMedGoogle Scholar
  4. Ugurel S, Rappl G, Tilgen W, et al.: Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res 2001, 7: 1282–6.PubMedGoogle Scholar
  5. Hauschild A, Engel G, Brenner W, et al.: Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol 1999, 140: 1065–71. 10.1046/j.1365-2133.1999.02905.xPubMedView ArticleGoogle Scholar
  6. Hauschild A, Engel G, Brenner W, et al.: S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 1999, 56: 338–44. 10.1159/000011989PubMedView ArticleGoogle Scholar
  7. Guo HB, Stoffel-Wagner B, Bierwirth T, et al.: Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer 1995, 31A: 924–8.PubMedView ArticleGoogle Scholar
  8. Henze G, Dummer R, Joller-Jemelka HI, et al.: Serum S100--a marker for disease monitoring in metastatic melanoma. Dermatology 1997, 194: 208–12. 10.1159/000246103PubMedView ArticleGoogle Scholar
  9. Streit S, Mestel DS, Schmidt M, et al.: FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br J Cancer 2006, 94: 1879–86. 10.1038/sj.bjc.6603181PubMed CentralPubMedView ArticleGoogle Scholar
  10. Tsao H, Zhang X, Fowlkes K, et al.: Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 2000, 60: 1800–4.PubMedGoogle Scholar
  11. Davies H, Bignell GR, Cox C, et al.: Mutations of the BRAF gene in human cancer. Nature 2002, 417: 949–54. 10.1038/nature00766PubMedView ArticleGoogle Scholar
  12. Okamoto I, Roka F, Krogler J, et al.: The EGF A61G polymorphism is associated with disease-free period and survival in malignant melanoma. J Invest Dermatol 2006, 126: 2242–6. 10.1038/sj.jid.5700377PubMedView ArticleGoogle Scholar
  13. Frey UH, Eisenhardt A, Lummen G, et al.: The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer. Cancer Epidemiol Biomarkers Prev 2005, 14: 871–7. 10.1158/1055-9965.EPI-04-0720PubMedView ArticleGoogle Scholar
  14. Frey UH, Alakus H, Wohlschlaeger J, et al.: GNAS1 T393C polymorphism and survival in patients with sporadic colorectal cancer. Clin Cancer Res 2005, 11: 5071–7. 10.1158/1078-0432.CCR-05-0472PubMedView ArticleGoogle Scholar
  15. Frey UH, Nuckel H, Sellmann L, et al.: The GNAS1 T393C polymorphism is associated with disease progression and survival in chronic lymphocytic leukemia. Clin Cancer Res 2006, 12: 5686–92. 10.1158/1078-0432.CCR-06-0288PubMedView ArticleGoogle Scholar
  16. Frey UH, Lummen G, Jager T, et al.: The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma. Clin Cancer Res 2006, 12: 759–63. 10.1158/1078-0432.CCR-05-1722PubMedView ArticleGoogle Scholar
  17. Daaka Y, Luttrell LM, Lefkowitz RJ: Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 1997, 390: 88–91. 10.1038/36362PubMedView ArticleGoogle Scholar
  18. Krumins AM, Barber R: Examination of the effects of increasing Gs protein on beta2-adrenergic receptor, Gs, and adenylyl cyclase interactions. Biochem Pharmacol 1997, 54: 61–72. 10.1016/S0006-2952(97)00147-0PubMedView ArticleGoogle Scholar
  19. Yang X, Lee FY, Wand GS: Increased expression of Gs(alpha) enhances activation of the adenylyl cyclase signal transduction cascade. Mol Endocrinol 1997, 11: 1053–61. 10.1210/me.11.8.1053PubMedGoogle Scholar
  20. Yang W, White B, Spicer EK, et al.: Complex haplotype structure of the human GNAS gene identifies a recombination hotspot centred on a single nucleotide polymorphism widely used in association studies. Pharmacogenetics 2004, 14: 741–7. 10.1097/00008571-200411000-00005PubMedView ArticleGoogle Scholar
  21. Siffert W, Forster P, Jockel KH, et al.: Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J Am Soc Nephrol 1999, 10: 1921–30.PubMedGoogle Scholar
  22. Balch CM, Buzaid AC, Soong SJ, et al.: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19: 3635–48.PubMedGoogle Scholar
  23. Pho L, Grossman D, Leachman SA: Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. Curr Opin Oncol 2006, 18: 173–9. 10.1097/01.cco.0000208791.22442.09PubMedView ArticleGoogle Scholar
  24. Nikolova PN, Pawelec GP, Mihailova SM, et al.: Association of cytokine gene polymorphisms with malignant melanoma in Caucasian population. Cancer Immunol Immunother 2007, 56: 371–9.PubMedView ArticleGoogle Scholar
  25. Martinez-Escribano JA, Moya-Quiles MR, Muro M, et al.: Interleukin-10, interleukin-6 and interferon-gamma gene polymorphisms in melanoma patients. Melanoma Res 2002, 12: 465–9. 10.1097/00008390-200209000-00008PubMedView ArticleGoogle Scholar
  26. Buettner PG, Leiter U, Eigentler TK, et al.: Development of prognostic factors and survival in cutaneous melanoma over 25 years: an analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. Cancer 2005, 103: 616–24. 10.1002/cncr.20816PubMedView ArticleGoogle Scholar
  27. Duan J, Wainwright MS, Comeron JM, et al.: Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 2003, 12: 205–16. 10.1093/hmg/ddg055PubMedView ArticleGoogle Scholar
  28. Capon F, Allen MH, Ameen M, et al.: A synonymous SNP of the corneodesmosin gene leads to increased mRNA stability and demonstrates association with psoriasis across diverse ethnic groups. Hum Mol Genet 2004, 13: 2361–8. 10.1093/hmg/ddh273PubMedView ArticleGoogle Scholar
  29. Tierney MJ, Medcalf RL: Plasminogen activator inhibitor type 2 contains mRNA instability elements within exon 4 of the coding region. Sequence homology to coding region instability determinants in other mRNAs. J Biol Chem 2001, 276: 13675–84.PubMedGoogle Scholar
  30. Dumaz N, Light Y, Marais R: Cyclic AMP blocks cell growth through Raf-1-dependent and Raf-1-independent mechanisms. Mol Cell Biol 2002, 22: 3717–28. 10.1128/MCB.22.11.3717-3728.2002PubMed CentralPubMedView ArticleGoogle Scholar
  31. Kadekaro AL, Kanto H, Kavanagh R, et al.: Significance of the melanocortin 1 receptor in regulating human melanocyte pigmentation, proliferation, and survival. Ann N Y Acad Sci 2003, 994: 359–65. 10.1111/j.1749-6632.2003.tb03200.xPubMedView ArticleGoogle Scholar
  32. Hunt G, Todd C, Cresswell JE, et al.: Alpha-melanocyte stimulating hormone and its analogue Nle4DPhe7 alpha-MSH affect morphology, tyrosinase activity and melanogenesis in cultured human melanocytes. J Cell Sci 1994,107(Pt 1):205–11.PubMedGoogle Scholar
  33. Dumaz N, Hayward R, Martin J, et al.: In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 2006, 66: 9483–91. 10.1158/0008-5472.CAN-05-4227PubMedView ArticleGoogle Scholar
  34. Karasarides M, Chiloeches A, Hayward R, et al.: B-RAF is a therapeutic target in melanoma. Oncogene 2004, 23: 6292–8. 10.1038/sj.onc.1207785PubMedView ArticleGoogle Scholar
  35. Hingorani SR, Jacobetz MA, Robertson GP, et al.: Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 2003, 63: 5198–202.PubMedGoogle Scholar
  36. Davies H, Bignell GR, Cox C, et al.: Mutations of the BRAF gene in human cancer. Nature 2002, 417: 949–54. 10.1038/nature00766PubMedView ArticleGoogle Scholar

Copyright

© I. Holzapfel Publishers 2010

Advertisement